Brown Brothers Harriman & Co. Sells 4,148 Shares of Sanofi (NASDAQ:SNY)

Brown Brothers Harriman & Co. decreased its position in shares of Sanofi (NASDAQ:SNY) by 89.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 500 shares of the company’s stock after selling 4,148 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Sanofi were worth $29,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in SNY. Northwest Investment Counselors LLC purchased a new stake in Sanofi during the third quarter valued at about $29,000. POM Investment Strategies LLC purchased a new stake in shares of Sanofi during the 2nd quarter valued at approximately $25,000. Concord Wealth Partners boosted its holdings in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the period. Arrow Financial Corp bought a new stake in Sanofi during the 2nd quarter valued at $35,000. Finally, Fortitude Family Office LLC lifted its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.9 %

Shares of SNY stock opened at $48.72 on Friday. The company has a market capitalization of $123.64 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The business’s fifty day moving average is $53.17 and its 200 day moving average is $52.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the firm posted $2.55 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts anticipate that Sanofi will post 4.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SNY shares. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.